US equities |
NVDA $239.76 ▲+2.49% SPCX $169.67 ▲+6.74% MU $1,060.34 ▼-1.35% TSLA $380.93 ▲+2.79% SNDK $1,693.14 ▼-1.56% MSFT $528.51 ▲+2.12% INTC $116.44 ▼-2.42% META $743.71 ▲+2.15%
FinancialContent

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.620 +0.060 (+3.85%)
Delayed Quote Updated: 3:17 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Transformative Strategy to Accelerate Growth
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
From Innate Pharma SA
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Releases Its 2025 Financial Calendar
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday ↗
 
Via Benzinga
News headline image
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Half 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Upcoming Investor Conference
From Innate Pharma
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
From Innate Pharma SA
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! 
Via InvestorPlace
News headline image
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >